Antibody surrogates for therapeutics, in vivo imaging,
and in vitro diagnostics
Antibody surrogates for therapeutics, in vivo imaging,
Antibody surrogates for
therapeutics, in vivo imaging,
and in vitro diagnostics
Antibody surrogates for
therapeutics, in vivo imaging,
and in vitro diagnostics
Indi Molecular is developing protein catalyzed capture agents (PCCs) as a small molecule replacement for antibodies in therapeutics, in vivo imaging, and in vitro diagnostics. The PCC platform allows us to build fully synthetic small peptides against specific epitopes of the desired target protein. Affinity and specificity are equivalent or superior to monoclonal antibodies.
We’ve achieved picomolar binding affinities. PCCs are the synthetic equivalent of monoclonal antibodies, offering the small size (< 4 kD) and biophysical properties of a small molecule drug.
Specificity
Specific to the chosen epitope of the desired target protein
Affinity
Pico-molar and low nano-molar binding affinities
Developable
Fully synthetic small peptides for rapid and robust manufacturing